Tharimmune, Inc. announced on August 13, 2025, a significant expansion of its intellectual property portfolio for TH-104, its novel transmucosal film. New patents have been recently granted and allowed across key global markets.
These patents will enable the company's long-term strategy of pursuing broader indications for the technology. This begins with its lead program as a critical medical countermeasure for military and first responders against high-potency opioids.
The securing of these global patents strengthens TH-104's market position and provides a robust foundation for future development and commercialization. This intellectual property protection is vital for the company's competitive advantage.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.